Loading
A phase 3 trial of Ibandronic acid and Zoledronic acid in Multiple myeloma, run by Hoffmann-La Roche, recorded as terminated on the registry.
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma is a phase 3 interventional study registered as NCT02739594 by Hoffmann-La Roche, with 89 participants recorded, started 2006-02 and due to reach its primary completion in 2009-04. Interventions recorded: Ibandronate, Zoledronate. Conditions recorded: Multiple Myeloma.
Linked to the drug Ibandronic acid because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
89 enrolled.
95% CI 2.7 to 23.1; Figures from the ClinicalTrials.gov results section (first posted 2016-07-22), not from a publication · 95% CI 4.2 to 26.8
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Participants With Deterioration in Renal Function According to Reduction in Creatinine Clearance (CrCl) From Baseline to Week 44primary | Ibandronate | 41 | 9.8% | - | - | link |
| Zoledronate | 40 | 12.5% |
Shares Ibandronic acid, Zoledronic acid and the tag pipeline.
Shares Ibandronic acid and the tag pipeline.
Shares Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Zoledronic acid and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.